Curriculum Vitae
ROBERT A. NAGOURNEY, M.D.
750 E. 29th Street, Long Beach, CA 90806
Ph: 562-989-6455, Fx: 562-989-8160
PLACE OF BIRTH: Bridgeport, Connecticut
CITIZENSHIP: USA
UNDERGRADUATE EDUCATION:
1971 - 1975 Boston University, Boston, Massachusetts, BA, Chemistry
MEDICAL EDUCATION:
1979 McGill University - M.D., Montreal, Canada
POST GRADUATE EDUCATION:
Residency
1979 – 1982 Internal Medicine, University of California, Irvine, Long Beach VA Medical Center
Fellowship
1982 - 1984 Medical Oncology, Georgetown University Hospital, Washington, D.C.
Fellowship Hematology
1984 - 1985 Scripps Clinic & Research Institute, La Jolla, California
HONORS:
Boston University, graduation with Distinction in Biochemistry, Summa Cum Laude, Phi Beta Kappa
McGill University, University Scholar
Recipient of the Scripps Institute Young Investigator Award, American College of Physicians Young Investigator Forum
CERTIFICATION BOARDS:
1982 Internal Medicine
1985 Medical Oncology
1986 Hematology
MEDICAL LICENSURE:
California - G043263
Virginia – 0101035589
EMPLOYMENT HISTORY:
2003 to present Medical Director, Malcolm C. Todd, MD Cancer Institute, Long Beach Memorial Medical Center, Long Beach, CA
1994 to present Rational Therapeutics, Inc., Long Beach, CA, Medical and Laboratory Director
1986 to present Oncology Hematology Consultants, Long Beach, CA, Attending Hematologist/Oncologist
1987 to present University of California, Irvine, Adjunct Assistant Professor, Pharmacology
1991 to 1994 Long Beach Memorial Medical Center, Memorial Cancer Institute, Director of Experimental Therapeutics
1987 to 1991 Long Beach Memorial Medical Center, Memorial Cancer Institute, Senior Investigator
1986 to 1991 Oncotech, Inc., Irvine, CA, Vice President for Clinical Services
MEDICAL SCHOOL SERVICE:
Annual Oncology Series: Mechanisms of Disease
Examination of the Patient course
Attending physician at Hematology/Oncology Clinic, University of California Irvine Medical Center
Cancer Education Committee
Pharmacology Core Curriculum – Anti-Cancer Drugs: 2nd Year lectures
HOSPITAL AFFILIATIONS:
Long Beach Memorial Medical Center, Long Beach, CA
Orange Coast Memorial Medical Center, Fountain Valley, CA
UCI Medical Center, Orange, CA
PROFESSIONAL/MEDICAL MEMBERSHIPS & AFFILIATIONS:
American Association for Cancer Research (AACR)
American Society of Clinical Oncology (ASCO)
Gynecology Oncology Group (GOG)
Medical Oncology Association of Southern California (MOASC)
American College of Physicians (ACP)
JOURNAL REVIEWER:
Gynecologic Oncology, 2004, 2003
Clinical Lymphoma, 2004, 2003
Clinical Breast Cancer, 2005, 2004, 2003, 2002
Clinical Cancer Research, 2001
British Journal of Cancer, 2004, 2003, 2002, 2001, 2000, 1999, 1998, 1992
Journal of Medicinal Foods, 2006, 2005, 2004, 2001, 2000, 1999, 1998
American Journal of Obstetrics and Gynecology, 1997, 1991
Blood, 1995
Cancer Investigation, 1995
Cancer Research, 1994
Oncology Research, 1992
European Journal of Cancer and Clinical Oncology, 1986
Cancer Treatment Reports, 1983
PRINCIPAL INVESTIGATOR & GRANT SUPPORT
Memorial Medical Center Foundation, A Study to Assess Clinical Outcomes, Quality of Life and Cost Efficacy of Assay Directed Therapy in the Treatment of Advanced or Recurrent Human Malignancies, July 2003.
Glaxo SmithKline Phase II Topotecan plus capecitabine for advanced recurrent breast cancer. Jan 2003.
Eli Lilly Company, Phase II Carboplatin plus gemcitabine in recurrent breast cancer. Jan 2002
GOG Phase II Evaluation of Gemcitabine and Cisplatin in Recurrent, Platinum Resistant and Refractory Ovarian and Peritoneal Carcinoma. GOG Protocol #0126L, Jan 2001.
GOG Phase II Evaluation of Gemcitabine and Cisplatin in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix. GOG Protocol #0127-Q, Jan 2001.
Cell Therapeutics: Ex-Vivo Analysis of Trisenox (As203) in Human Tumor Primary Cultures. 2001.
Long Beach Memorial Medical Center, Pilot Study of Oral Limonene & Lovastatin in Refractory Solid Tumors. MHS-Research Council #018-00. 2001.
Smith Kline Beecham: Phase II Trial – Ex Vivo Analysis of Topotecan in Breast, Colon, Prostate and Non-Small-Cell Lung Cancers, 2000
Eli Lilly: Phase II Trial of Cisplatin Plus Gemcitabine in Relapsed Ovarian Carcinoma, 1997
Eli Lilly: Phase II Trial of Cisplatin Plus Gemcitabine in Relapsed Breast Carcinoma, 1997
Berlex Laboratories, Inc.: Phase II Trial of Cisplatin & Fludarabine in Relapsed Intermediate & High Grade B-Cell Non-Hodgkins Lymphoma, 1997
Memorial Hospital Medical Center Foundation, "The Clinical Reversal of Drug Resistance in Human Malignant Neoplasms", January 1986.
National Cancer Institute #1RCA43432-01. "The Detection and Circumvention of Acquired Drug Resistance"
Ortho Biotech: Prediction of Response to 2-CDA in Non-Hodgkin's Lymphoma
INVITED LECTURER
- Medical University of South Carolina, Charleston, SC December 7 & 8, 2006
- Macomb Hospital, Warren, MI September 22, 2006
- Lilly Metastatic Breast Cancer Conference, Sao Paulo, Brazil August 4 & 5, 2006
- Wellness Community, South Bay, May 17, 2006
- Leukemia/Lymphoma Society, Poway, CA May 17, 2006
- St. Joe’s Hospital, Phoenix, AZ, March 16, 2006
- University of Mississippi Medical Center, Jackson, MS, February 2, 2006
- Doctor’s Hospital of Modesto, CA, October 19, 2005
- University of California, Irvine, GYN/Onc Ground Rounds, July 8, 2005
- Mayo Medical Center, Phoenix, AZ June 8, 2005
- Lilly Speaker Program, Phoenix, AZ June 7, 2005
- Hollywood Presbyterian Hospital, Hollywood, CA May 11, 2005
- Queen Mary, Long Beach, CA, Safeway/Vons Pharmacists, April 5, 2005
- Oncology Regional Medical Conference, Beijing, China, June 25-27, 2004
- Hong Kong Sanatorium & Hospital, Queen Elizabeth Hospital, Hong Kong, June 24, 2004
- Center For Business Intelligence, Combination Drug Therapies, Philadelphia, PA April 2004
- Santa Rosa Memorial Hospital, Santa Rosa, CA April 2004
- Memorial Care Women’s Breast Conference & Health Fair, Long Beach, CA September 2003
- Pomona Valley Hospital Medical Center, Pomona, CA September 2003
- Simon Kramer Cancer Institute, New Philadelphia, PA August 2003
- Magee-Women’s Hospital, Pittsburgh, PA August 2003
- The Future of Breast Cancer Symposium, Banff, Alberta, Canada, August 2, 2003
- Nevada Oncology Society, Las Vegas, NV June 25, 2003
- Wellness Community, Redondo Beach, CA June 18, 2003
- ASCO Update, Long Beach, CA June 17, 2003
- 2003 Oncology Global Medical Conference, Lilly Oncology, Indianapolis, IN May 30, 2003
- St. Mary’s Medical Center, Apple Valley, CA May 14, 2003
- University of California, Irvine, Oncology Grand Rounds, May 6, 2003
- Illinois Masonic Hospital, Chicago, IL March 18, 2003
- Cancer Health Associates, Munster, IN March 17, 2003
- Mercy Medical Center, Redding, CA February 25, 2003
- Mt. Diablo Regional Cancer Center, Concord, CA February 24, 2003
- Naval Medical Center, San Diego, CA February 21, 2003
- Great Debates In Gyn Oncology, SGO Symposium, New Orleans, LA February 2, 2003
- Yuma, AZ January 28, 2003
- Fountain Valley Hospital, Fountain Valley, CA January 23, 2003
- Mercy Anderson Hospital, Cincinnati, OH December 18, 2003
- Wellness Community, Cincinnati, OH December 17, 2003
- Good Samaritan Hospital, Cincinnati, OH December 17, 2003
- Bethesda Hospital-North, Cincinnati, OH December 17, 2003
- Hematology/Oncology Group of Fresno, CA October 22, 2002
- Lilly Oncology Regional Advisory Board, Los Angeles, CA October 12, 2002
- Memorial Hospital, Modesto, CA October 2, 2002
- Lilly Oncology Regional Advisory Board, San Francisco, CA September 27, 2002
- Genetics MDRU Symposium, UC Davis, August 21, 2002
- Kaiser Foundation Hospital, Oncology Pharmacists Retreat, Marina Del Rey, CA June 2, 2002
- Vermont Center for Cancer Medicine, Colchester, VT May 2, 2002
- Dartmouth Hitchcock Medical Center, Lebanon, NH May 2, 2002University of California,
- Irvine, Pharmocology Dept., Orange, CA March 28, 2002
- Parkview Community Hospital Medical Center, Riverside, CA March 22, 2002
- Marion Medical Center, Santa Maria, CA March 15, 2002
- St. Mary’s Medical Center, Apple Valley, California, March 8, 2002
- California State University, Long Beach, California, February 27, 2002
- Kuakini Medical Center, Honolulu, Hawaii, February 14, 2002
- Straub Clinic & Hospital, Honolulu, Hawaii, February 11, 2002
- Los Angeles Hematology Oncology, Glendale, CA, February 5, 2002
- Fountain Valley Medical Center, Fountain Valley, CA, February 8, 2002
- St. Joseph’s Cancer Center, Orange, CA, January 29, 2002
- Orange County Pharmacist Association, Newport Beach, CA, January 24, 2002
- Valley Tumor Medical Group, Lancaster, CA, January 15, 2002
- Puerto Vallarta, Mexico, Chair, Women’s Cancers, Latin American Regional Medical Conference, December 8-9, 2001
- Palo Verde Hematology/Oncology, Glendale, AZ November 15, 2001
- Scottsdale Healthcare Medical Center, Scottsdale, AZ November 15, 2001
- Colorado Hematology and Oncology, Denver, CO November 25, 2001
- Penrose Centura Health, Colorado Springs, CO October 26, 2001
- Pomona Valley Hospital Med. Ctr., Pomona, CA September 20, 2001
- UTMB, Galveston, TX August 8, 2001
- Glen Falls Cancer Center, Glen Falls, NY, July 20, 2001
- University of Rochester, Rochester, NY July 19, 2001
- SUNY, Syracuse, NY, July 19, 2001
- US Oncology Physicians, Saratoga Springs, NY July 19, 2001
- South Org. Cty. Hematology and Oncology Association, Mission Viejo, CA July 12, 2001
- Hematology/Oncology Associate, Phoenix, AZ June 8, 2001
- Arizona Cancer Center, University of Arizona, Tucson, AZ June 8, 2001
- Monterey Bay, California, May 3, 2001
- California Cancer Center, Fresno, CA April 18, 2001
- Cancer Care Associates of Fresno, Fresno, CA April 17, 2001
- Kaweah Delta Cancer Care Center, Visalia, CA April 17, 2001
- Hematology-Oncology Medical Group of Fresno, Fresno, CA April 16, 2001
- John Wayne Cancer Institute, Santa Monica, CA March 11, 2001
- Good Samaritan Hospital, Cincinnati, OH March 16, 2001
- St. Vincent’s Hospital, Indianapolis, IN March 15, 2001
- Memorial Regional Cancer Center, Modesto, CA March 8, 2001
- Muhlenberg Regional Medical Center, Plainfield, NJ March 2, 2001
- Northshore University Hospital, Manhasset, NY March 1, 2001
- Clara Moss Medical Center, Belleville, NJ March 1, 2001
- Mt. Sinai Medical Center, New York, NY February 28, 2001
- New York University, Kaplan Cancer Center, February 28, 2001
- California State University, Long Beach, February 9, 2001
- University of Oklahoma, Health Sciences, Tulsa, OK February 6, 2001
- Cancer Center Associates, Tulsa, OK February 6, 2001
- Harbor-UCLA Medical Center, Los Angeles, CA November 8, 2000
- Benefis Healthcare, Great Falls, MT November 2, 2000
- SmithKline Beecham Joint Oncology Program, Charleston, SC October 27, 2000
- UTMB, Galveston, TX October 17, 2000
- Los Salinas Medical Center, Salinas, CA October 5, 2000
- Ovarian Cancer Research Symp. Marsha Rivkin Center, Seattle, WA September 15, 2000
- Bristol-Myers Squibb Oncology, Long Beach, CA September 14, 2000
- ALIMTA Advisory Board Meeting, Colorado Springs, CO August 17, 2000
- Sutter Cancer Center, Sacramento, CA August 10, 2000
- Birmingham, AL, August 4, 2000
- Olive View Medical Center, Sylmar, CA June 6, 2000
- St. Joes Hospital, Bellingham, WA May 9, 2000
- Oncology Medical Center of North Orange County, Vista, CA May 4, 2000
- Good Samaritan Hospital, Cincinnati, OH April 13, 2000
- Ohio State University, Columbus, OH April 13, 2000
- Evergreen Medical Center, Kirkland, Washington, March 24, 2000
- Comprehensive Blood & Cancer Center, Bakersfield, California, March 14, 2000
- Brooke Army Medical Center, San Antonio, Texas, March 2, 2000
- Doctors Hospital of Laredo, Texas, March 2, 2000
- Apple Valley and Ontario, California, February 22, 2000
- University of California Irvine, Department of OBGYN-Grand Rounds, February 18, 2000
- American Cancer Society, Palo Alto, CA, February 3, 2000
- Irvine Medical Center, Irvine, CA, January 24, 2000
- University of Kansas, Kansas City, MO, January 21, 2000
- St. Luke’s Hospital, Kansas City, MO, January 20, 2000
- Chemotherapy Foundation Symposium, New York, NY, November 4, 1999
- Abilene Regional Medical Center, Abilene, TX, October 19, 1999
- University of Maryland, Baltimore, MD, October 11, 1999
- University of Chicago, Chicago, IL August 30, 1999
- Nashville Oncology Society, Nashville, TN, August 19, 1999
- Prostate Cancer Research Institute National Conference, Long Beach, CA, August 1, 1999
- Community Hospital of Los Gatos, San Jose, CA, July 20, 1999
- Cancer Prevention & Treatment Center of Central Coast, Soquel, CA, July 20, 1999
- Comprehensive Cancer Care II, Innovative Uses of Conventional Treatment, Arlington, VA, June 13, 1999
- Cancer Foundation of Santa Barbara, Novel Approaches to Chemotherapy, June 1, 1999
- Long Beach Memorial Medical Center, Mini Symposium on Prostate Cancer, May 25, 1999
- Lilly Oncology Global Medical Conference, Indianapolis, IN, May 12, 1999
- Hematology/Oncology Med. Group of Orange County, Tustin, CA, April 27, 1999
- South Orange County Hematology/Oncology. Assoc., Mission Viejo, CA, March 30, 1999
- New York University, New York, NY, March 24, 1999
- Gemzar Investigator’s Meeting, New Orleans, March 11-13, 1999
- Orthomolecular Health Medicine, San Francisco, CA, February 26, 1999
- Wilshire Oncology Medical Group, Rancho Cucamonga, CA, February 18, 1999
- Long Beach Memorial Medical Center, Garlic: Medicinal Food or Nutritious Medicine, February 18, 1999
- Kaeweah Delta Cancer Care Program, Visalia, CA, February 17, 1999
- Hematology/Oncology Group of Fresno, Fresno, CA, February 16, 1999
- Washington Hospital Center, Washington, DC, February 12, 1999
- Howard University, Washington, DC February 11, 1999
MANUSCRIPTS:
Nagourney RA. Chemosensitivity and resistance assays: a systematic review? J Clin Oncol. 2005 May 20;23(15):3640-1; author reply 3646-8. Review. No abstract available.
Brewer C, Blessing J, Nagourney RA, et al. Cisplatin plus Gemcitabine in Platinum Refractory Ovarian or Primary Peritoneal Cancer: A Phase II Study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Apr 24
Nagourney RA. Ex Vivo Programmed Cell Death and the Prediction of Response to Chemotherapy. Current Treatment Options in Oncology, Vol 7, issue 2, March 2006.
Brewer C, Blessing J, McMeekin S, et al. Cisplatin plus Gemcitabine in Previously Treated Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group. Gyn Onc, 100(2):385-8, Feb 2006
RA Nagourney, BL Sommers, SM Harper, S Radecki & SS Evans. Ex vivo Analysis of Topotecan: Advancing the Application of Laboratory-Based Clinical Therapeutics. Br J of Canc 89, 1789-1795 (2003)
Nagourney RA, Brewer CA, Radecki S, Kidder W, Sommers B, Evans SS, Minor D, DiSaia, P.: A Phase II Trial of Gemcitabine Plus Cisplatin Repeating Doublet Therapy In Previously Treated, Relapsed Ovarian Cancer Patients. Gyn Onc 88, 35-39 (2003)
Sovak M, Seligson AL, Konas M, Hajduch M, Dolezal M, Machala M, Nagourney R.: PC-SPES in Prostate Cancer: An Herbal Mixture Currently Containing Warfarin and Previously Diethylstilbestrol and Indomethacin. J Natl Cancer Inst., Sept 4, 2002
Chun H, Castellvi-Bel S, Wang Z, Plaeger S, Nagourney RA, et al: TCL-1 and MTCP-1 and TML-1 Gene Expression Profile In Non-Leukemic Clonal Proliferations Associated With Ataxia-Telangiectasia. Int J. Cancer: 97, 726-731, 2002
Nagourney RA. Gemcitabine Plus Cisplatin in Breast Cancer. Oncol, Volume 15, Number 2, Supplement, January 2001.
Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS: Gemcitabine Plus Cisplatin Repeating Doublet Therapy In Relapsed, Pretreated Breast Cancer. J Clin Oncol, Vol 18, Issue 11, 2000:2245-2249
Nagourney RA: Letter to the Editor. Gynecologic Oncol, 76(1):143, 2000
Nagourney RA: Oral Limonene: Combined prenylation inhibitor therapy of cancer. J Med Food, Vol 1, No 2, 83-88, 1998
Nagourney RA: Garlic: Medicinal Food or Nutritious Medicine? J Med Food Vol 1, No 1:13-28, 1998
Nagourney RA, Evans SS, Messenger JC, Dill PA, et al: 2-Chlorodeoxyadenosine activity and cross-resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 67:10-14, 1993
Nagourney RA: Cytotoxic chemotherapeutic agents: Effective in vitro probes for the biology of human cancers. Proceedings International Symposium on Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma. 263-69, 1992
Nagourney RA, Evans SS, Messenger JC, Aziz D, Su YZ: Biochemical and electrochemical characterization of acquired drug resistance in human lymphatic malignancy. International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma 1992
Nagourney RA: Multi-drug resistance in acute myeloid leukemia. J Natl Cancer Inst (c) 83:1418-1419, 1991
Weisenthal LM, Nagourney RA, Moran EM, Kern DH: Laboratory detection of drug resistance and extreme drug resistance. Clinical Management of the Drug-Resistant Cancer Patient: New Options in Clinical Oncology. Memorial Medical Center Foundation Press 70-81, 1991
Boullier B, Bosanquet AG, Nagourney RA, Weisenthal LM: In vitro enhancement of doxorubicin, vincristine, and melphalan cytotoxicity against fresh human leukemic lymphocytes. Hellman, K and Carter, SK (eds) Cancer Treatment Reviews, Academic Press 17:90-91, 1990
Weisenthal LM, Nagourney RA, Kanan, PG, Kern DH: Laboratory assays to predict response to cancer chemotherapy: After 35 years are they suitable for the clinic? Advances in Clin Oncol 1:127-143, 1989
Weisenthal LM, Nagourney RA, Kern DH: Extreme drug resistance can be accurately detected in fresh specimens of human breast cancer and has implications for adjuvant chemotherapy. In Salman, S (ed) Adjuvant Therapy of Cancer, Volume VI. WB Saunders, Philadelphia, USA, 339-348, 1990
Nagourney RA, Messenger JC, Kern DH, and Weisenthal LM: Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues. Cancer Chemother Pharmacol 26:318-322, 1990
Kurohara W, Colman M, Nagourney RA, Weisenthal LM, et al: Radiation response of cells from human tumor biopsies as assessed by a dye exclusion technique: a possible predictive assay. Int J Radiat Biol 56:767-770, 1989
Weisenthal LM, Nagourney RA, Kern DH, et al: Approach to the clinical circumvention of drug resistance utilizing a non-clonogenic in vitro assay measuring the effects of drugs, radiation and interleukin-II on largely non-dividing cells. Adv Clin Oncol 1:91-111, 1989
Weisenthal LM, Su YZ, Duarte TE, Nagourney RA: Non clonogenic in vitro assays for predicting sensitivity to cancer chemotherapy. Prog Clin Bio Res 276:75-92, 1988
Weisenthal LM, Su YZ, Duarte TE, Dill PL, Nagourney, RA: Perturbation of in vitro resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C. Cancer Treat Rev 1239-1247, 1987
Weisenthal LM, Su YZ, Duarte TE, Dill PL, Nagourney RA: Perturbation of in vitro drug resistance in human lymphatic neoplasms by agents known to interact with protein kinase C. II. C kinase inhibitors. Cancer Treat Rev 12:1239, 1987
Weisenthal LM, Su YZ, Duarte TE, Nagourney RA: Non-clonogenic, in vitro assays for predicting sensitivity to cancer chemotherapy, in T. Hall (ed), Prediction of Response to Cancer Chemotherapy. New York, NY, Alan R. Liss, Inc., 1987
Woolley PV, Von Hoff DD, Kyle GW, Kumar S, Nagourney RA, Luc TP, Mossman KL: Biology of colon cancer resistance to treatment. Biology and Treatment of Colorectal Cancer Metastases. Mastromarino, AJ (ed) Martinus Nijhoff, Boston, 1986
Nagourney RA, Hedaya R, Linnoila M, Schein PS: Carcinoid carcinomatous meningitis: A case report. An Intern Med; 102:6, 1985
Nagourney RA, Fox P, Schein PS: A comparison of the biological and biochemical properties of ACNU and chlorozotocin. Cancer Res 38:65-68, 1978
Panasci L, Green DC, Nagourney RA: A structure activity analysis of the chemical and biological parameters of chloroethylnitrosoureas in mice. Cancer Res 37:2615-2618, 1977
ABSTRACTS:
Nagourney RA, Kollin CA, Sommers B, Su YZ, Francisco F, Evans SS. Bortezomib combinations in ovarian cancer: Ex vivo analysis of activity and synergy in human tumor primary culture spheroids. (2158) Amer Assoc for Canc Res, 2006. (abst)
Nagourney RA, Sommers BA, Evans SS, Kollin C, Su YZ, Evans T, Islas J, Kakkis J, Tabar L. Casting-type calcification breast cancer: Assessment of response to cytotoxic insult in human tumor primary culture spheroids. (680) Amer Soc of Clin Oncol 24, 2005 (abst)
Blitzer J, McConnell D, Cullinane C, Grant S, Azaren K, Asciuto T, Shbeeb I, Islas J, Sommers B, Jacobs C, Davis S, Byczynski K, Nagourney RA. Assay directed chemotherapy in advanced solid tumors: A phase II trial. (9692) Amer Soc of Clin Oncol 24, 2005 (abst)
Kollin C, Su YZ, Evans SS, Nagourney RA. The effects of EGFr modulation by Cetuximab & Gefitinib in human tumor primary culture microspheroids. (2170) Amer Assoc of Canc Res 46, 2005 (abst)
Nagourney RA, Kollin C, Su YZ, Evans SS. Geldenamycin & 17-allylamino-17-demethoxygeldenamycin alone and in combination with cytotoxic drugs in human tumor primary cultures. (1713) Amer Assoc of Canc Res 46, 2005 (abst)
Evans S, Brewer C, Kollin C, Su YZ, Nagourney RA. The role of targeted therapies in ovarian cancer: Examination of drug activity in human primary culture spheroids. (5324) Amer Assoc of Canc Res 46, 2005 (abst)
Nagourney RA, Link J, Sommers B. Carboplatin & gemcitabine repeating doublet in recurrent breast cancer. (851) Amer Soc Clin Oncol 32, 2004 (abst)
Nagourney RA, Su, YZ, Horlick D, Chow C, Kollin C, Evans SS. Bortezomib (PS-341) alone and in combination with cytotoxic drugs: Ex vivo analysis in human tumor primary cultures. (3690) Amer Assoc of Canc Res 45, 2004 (abst)
Evans SS, Brewer C, Su YZ, Yeung C, Chow C, Horlick D, Kollin C, Nagourney RA. Gemcitabine/Antifol combinations in human tumor primary cultures: Potential role in gynecologic malignancies. (4446) Amer Assoc of Canc Res 45, 2004 (abst)
Nagourney RA, Chow C, Kollin C, et al. Effect of gefitinib (Iressa, ZD 1839) in human tumor primary cultures: Possible insights into drug actions. (3801) Amer Assoc of Canc Res 44, 870, 2003 (abst)
Brewer CA, Segna R, Sommers BL, et al. Capecitabine and vinorelbine in refractory ovarian malignancies. A pilot study. (482) Amer Assoc of Canc Res 44, 110, 2003 (abst)
Nagourney RA, Isaacs J., Bosserman L, et al. Adrenocortical carcinoma therapy with cisplatin & gemcitabine: Laboratory and clinical correlates. (1786) Proc Amer Soc Clin Oncol 22, 445, 2003 (abstr)
Kollin CA, Evans SS, Su, Y-Z Su, et al. A direct comparison of paclitaxel and docetaxel activities in human tumors. (655) Proc Amer Soc Clin Oncol 22, 163, 2003 (abstr)
Nagourney RA, Su YZ, Chow C, et al. Arsenic Trioxide (AS2O3-TrisenoxTM) Single Agent and Combination Activity in Human Lung, Colon, Breast and Ovarian Tumor Primary (1o) Cultures (2189) Proc Amer Soc Clin Oncol 21, 94b, 2002 (abstr)
Sovak M, Seligson AL, Konas M., et al. PC-SPES in Prostate Cancer: An Herbal Mixture Currently Containing Warfarin and Previously Diethylstilbestrol and Indomethacin. (LB152) Proc Amer Assoc Canc Res, Proceedings Supplement; 84-2002 (abstr)
Nagourney RA, Chow C, Su YZ, et al. Activity of ZD1839 (Iressa) Alone And Combined With Cytotoxic Drugs In Human Tumor Primary Cultures (3902). Proc Amer Assoc Canc Res 43:787, 2002. (abstr)
Su YZ, Spall D, Traill MA, et al. BEC, A Mixture Of Soloasodine Glycosides Reveals Cytotoxic Activity In Human Tumor Primary Culture Specimens: Pre-Clinical And Early Clinical Observations (1070). Proc Amer Assoc Canc Res 43:214, 2002 (abstr)
Nagourney RA, Block K, Spall D, et al. Ex-Vivo Assay (EVA?) Directed Cancer Chemotherapy: Feasibility and Utility in Clinical Practice (2162). Proc Amer Soc Clin Oncol 20, 99b, 2001 (abstr)
Evans SS, Chow C, Horlick, et al. Is Cisplatin & Gemcitabine Equivalent to Carboplatin & Gemcitabine? Yes and No (2145). Proc Amer Soc Clin Oncol 20, 103b, 2001 (abstr)
Nagourney RA, Su YZ, Chow C, et al. Anvirzel, an Extract of Nerium Oleander Reveals Cytotoxic Activity in Human Tumors (3412). Proc Amer Assoc Canc Res 42:634, 2001.
Su YZ, Horlick D, Harris C, et al. Synergy Between Topotecan & Other Cytotoxic Drugs in Human Tumors (1368). Proc Amer Assoc Canc Res 42:252, 2001 (abstr)
Evans SS, Chow C, Su Y, et al. Oxaliplatin vs Cisplatin Activity in Human Tumors (894). Proc Amer Soc Clin Oncol 19:228a, 2000 (abstr)
Dottino P, Evans SS, Segna R, et al. EVA? Assay-Directed Therapy of Advanced Ovarian Cancer. (1532) Proc Amer Soc Clin Oncol 19:387a, 2000 (abstr)
Nagourney RA, Chow C, Su Y, et al, Comparison of Cisplatin Combinations in Human Non-Small Cell Lung Cancer (NSCLC) (2144). Proc Amer Soc Clin Oncol 19:544a, 2000 (abstr)
Nagourney RA, Su, YZ, Evans SS, et al: BCLxL Expression in Human Tumors: Correlation with Ex-Vivo Drug Resistance Profiles in Primary Cultures. (2572) Proc Amer Assoc Canc Res 41:404, 2000 (abstr)
Nagourney RA, Evans SS, Chow C, Su Yz: Trastuzumab (Herceptin) enhancement of cytotoxic drug activity in human tumor primary cultures (475). San Antonio Breast Cancer Symposium, 57:1:116a, 1999 (abstr)
Su YZ, Evans SS, Blitzer JB, Priego V, Nagourney RA: Cisplatin (Cddp) & fludarabine (FAMP) in relapsed high (H) & intermediate (I)-grade non-Hodgkin’s lymphomas (NHL): Laboratory & clinical observations (142) Proc Amer Soc Clin Oncol 18:38a, 1999 (abstr)
Evans SS, Su YZ, Danskin J, Chow C, Horlick, Harris C, Nagourney RA: Activity profile of trimetrexate (TMTX) & 5-fluorouracil (5FU) in human tumors (740). Proc Amer Soc Clin Oncol 18:192a, 1999 (abstr)
Nagourney RA, Blitzer J, Forstoff C, Link J. Phase II trial of gemcitabine & cisplatin in heavily pretreated, relapsed breast cancer (428). Proc Amer Soc Clin. Oncol 18:113a, 1999 (abstr)
Evans SS, Chow C, Danskin JW, Su YZ, Nagourney RA: Gemcitabine synergy with nitrogen mustard in human tumors (3891). Proc Amer Assoc for Canc Res 40:590, 1999 (abstr)
Nagourney RA, Danskin JW, Chow C, Su YZ, Evans SS: Arsenic trioxide (As203) activity spectrum in human tumors (2626). Proc Amer Assoc for Canc Res 40:397,1999 (abstr)
Nagourney, RA, Dottino P, DiSaia P, Link J, Su YZ, Evans SS. Gemcitabine (dfdc) combination therapy: Current observations & future directions. Proc US Gemzar (Gemcitabine HCI) Investigators Meeting 1999
Kunkel LM, Evans SS, Dottino PJ, DiSaia PJ, Nagourney RA: Cisplatin (Cddp) & gemcitabine (dfdc) in relapsed ovarian cancer (1379). Proc Amer Soc Clin Oncol, 17:357a, 1998 (abst)
Nagourney, RA, Link J., Kunkel L & Evans SS: Phase II trial of cisplatin (Cddp) & gemcitabine (dfdc) in heavily pretreated breast cancer (619). Proc Amer Soc Clin Oncol 17:161a, 1998 (abstr)
Nagourney RA, Su YZ, Link J, DiSaia P & Evans SS: Gemcitabine synergy with cisplatin. Clinical and laboratory correlates (2118) Proc Amer Assoc for Canc Res 39:310, 1998 (abstr)
Su YZ, Evans SS, Chow CWY, Danskin JW, Nagourney RA: Tirapazamine activity and synergy with Cisplatin and Mitomycin C in human tumor primary cultures (2098) Proc Amer Assoc for Canc Res 39:307, 1998 (abstr)
Nagourney RA, Link J: Gemcitabine plus cisplatin in heavily pre-treated breast cancer (402) 20th Annual San Antonio Breast Cancer Symposium 46:93, 1997 (abstr)
Nagourney, RA Combined Prenylation Inhibitor Therapy in Drug Refractory Cancers (868) Proc Amer Soc Clin Oncol 16:246a, 1997 (abstr)
Nguyen B, Link JS, Nagourney RA: Phase II study of mifepristone (RU486) in metastatic breast cancer Roussel UCLAF 051-93 (646). Proc Amer Soc Clin Oncol 16:184a, 1997 (abstr)
Nagourney RA, Su YZ, Evans SS, Sovak M: Activity spectrum of BP-179, a novel hydrophilic taxoid: A comparison with paclitaxel in human tumor primary culture specimens (4114). Proc. Amer Assoc for Canc Res 38:612, 1997 (abstr)
Nagourney RA, Su YZ, Horlick D, Evans SS: Fludarabine synergy with cisplatin and nitrogen mustard in primary culture specimens from heavily pretreated leukemia and lymphoma patients (3178). Proc Amer Assoc for Canc Res 38:475, 1997 (abstr)
Nagourney RA, Krajewski S, Su YZ, Evans SS, Reed J: BCLxL expression is associated with drug resistance in human tumor specimens (908). Proc Amer Assoc. for Canc Res 38:136, 1997 (abstr)
Nagourney RA, Su YZ, Makalinao AJ, Ciarolla A, Evans SS: Preliminary analysis of betulinic acid in human tumor primary cultures (2724). Proc. Amer Assoc for Canc Res 37:399, 1996 (abstr)
Nagourney RA, Evans SS, Makalinao AJ, Su YZ: Gemcitabine activity in primary cultures of human cancer (2161). Proc. Amer Assoc for Canc Res 37:318, 1996 (abstr)
Nagourney RA, Makalinao AJ, Evans SS, Su YZ, Blitzer J, Lyons W: Laboratory-directed therapy for relapsed and refractory acute leukemias (1073). Proc Amer Soc Clin Oncol 15:363, 1996 (abstr)
Nagourney RA, Lung RC: Cost-efficacy of assay-directed therapy in non-small cell lung cancer (NSCLC) (1225). Proc Amer Soc Clin Oncol 15:402, 1996 (abstr)
Su YZ, Evans SS, Yamamoto R, Granger G, Nagourney RA: Plasma TNF-55kd & 75kd receptor levels correlated with drug induced cytotoxicity in primary cultures of human hematologic neoplasms (2786). Proc Amer Assoc Canc Res 36:468, 1995 (abstr)
Nagourney RA, Brown DM, Su YZ, Evans SS: DNA-degradation patterns associated with drug-induced cytotoxicity in human hematologic neoplasm primary cultures (66). Proc Amer Assoc Canc Res 36:11, 1995 (abstr)
Nagourney RA, Risbud A, Evans SS, Su YZ, Link J, Ciarolla A: Constitutive resistance to CDDP in human chronic lymphocytic leukemia (CLL) (1620) Proc. Amer Soc Clin Oncol 14:495, 1995 (abstr)
Nagourney RA, Risbud A, Blitzer J, Su YZ, Evans SS: Activity spectrum of topotecan in primary cultures of human neoplasms (1615). Proc. Amer Soc Clin Oncol 14:493, 1995 (abstr)
Nagourney RA, Minow R, Kattlove H, Su YZ, et al: Activity of 2-Chlorodeoxy adenosine (CDA) in CML blastic crises (BC) (1596). Proc Amer Soc Clin Oncol 14:489, 1995 (abstr)
Hendler SS, Sanchez RA, Nagourney RA, Lauermann MW, et al: PANAVIR: A novel therapy for HIV infection. Proc of the Tenth International Conference on AIDS. Yokohama, Japan, 1994 (abstr)
Nagourney RA, Hendler SS, Sanchez RA, Strayer G, et al: Phase I/II Trial of oral panavir for HIV infection. Proc of the Tenth International Conference on AIDS. Yokohama, Japan, 1221, 1994 (abstr)
Nagourney RA, Atiba J, Ciarolla A, Blitzer J: Pala plus 5-fluorouracil (5FU) /leucovorin (LV) in advanced gastric (G) and pancreatic (P) cancer (636). Proc. Amer Soc Clin Oncol 13:212, 1994 (abstr)
Nagourney RA, DeSwarte J, Weisenthal LM: Induction of cell death in vitro by dexamethasone in specimens of childhood acute lymphatic leukemia (ALL) predicts disease free survival (DFS):A 12 year follow up. Applications of Apoptosis: Programmed Cell Death. CHI Conference, La Jolla, CA 1994
Su YZ, Evans SS, Nagourney RA: Drug-induced cytoxicity (C) in human leukemia (HL) 1° degree cultures: Molecular & Cellular events. Proc Amer Assoc Canc Res (1861), 35:313, 1994 (abstr)
Nagourney RA, Su YZ, Evans SS: 2-Chlorodeoxyadenosine (CDA) interactions in vitro with radiation (R) & nitrogen mustard (NM) in primary cultures of human hematologic neoplasms (HN) (2524). Proc Amer Assoc Can Res 35:423, 1994 (abstr)
Nagourney RA, Atiba J, Ciarolla A, Blitzer J, Iyer P: PALA plus 5-fluorouracil (5FU/Leucovorin (LV) in advanced gastric (G) and pancreatic (P) cancer (660). Proc Amer Soc Clin Oncol 12:217, 1993 (abstr)
Nagourney RA, Weisenthal LM: Evidence that alkylator (ALK) drug resistance (DR) is the most important mechanism for the failure of chemotherapy in high grade and intermediate grade non-Hodgkin's lymphomas. Proc Amer Assoc Can Res 1822, 1993 (abstr)
GUEST EDITORIAL:
RA Nagourney. Chemosensitivity and Resistance Assays: A Systematic Review? Letter to the Editor, Journal of Clinical Oncology, Vol 23, No 15, May 20, 2005.
RA Nagourney. The Once and Future Role of the Platinum Agents in Advanced Breast Cancer. A Commentary. Clin Breast Canc, June 2004, 123.
RA Nagourney. Doctors Obligated to Keep an Open Mind About Alternative Treatments. Los Angeles Business Journal, January 18, 1999
RA Nagourney. When Less is More in the Treatment of Multiple Myeloma. Myeloma Today, 2:6, 10-11, 1997
RA Nagourney. A New Paradigm for Cancer Chemotherapy: COPE. May, 1993
BOOK CHAPTERS:
Kroep Jr, Peters GJ, Nagourney RA, Gemcitabine as a single agent and in combination. Nuceloside Analogues in Cancer Therapy. Academic Press, Amsterdam, 2006
Nagourney RA, "Cytotoxic Chemotherapeutic Agents": Effective In Vitro Probes for the Biology of Human Cancers". Proceedings International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, The Netherlands. 1992
Nagourney RA, Evans SS, Messenger JC, Aziz D, Su YZ: "Biochemical and Electrochemical Characterization of Acquired Drug Resistance in Human Lymphatic Malignancy". Proceedings International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, The Netherlands. 1992
Nagourney RA, Woolley PV. "Paraneoplasia", Progressive stages of malignant neoplastic growth, Han Kreiser (ed), Martinus Nijhoff, Publishers, 1986. AS-Dordrecht. Netherlands.
TEXTBOOKS:
Clinical Management of The Drug-Resistant Cancer Patient: New Options in Clinical Oncology, Nagourney RA, Sheikh KM (eds), Memorial Medical Center Foundation Press, Long Beach, 1991.
|